INTRODUCTION
As the prognosis for many childhood malignancies has improved the late effects of chemotherapy and radiotherapy have become more important. One of the principal differences between adults and children is that children grow. The Bristol paediatric oncology and paediatric endocrinology services have collaborated to investigate the effects of chemotherapy and craniospinal irradiation on the longitudinal growth of survivors. Figure 1 shows the longitudinal height-attained growth chart of a child who grew poorly following treatment for a medulloblastoma. Our experience, and that of others, is that children treated for brain tumours, head and neck tumours and some leukaemic children are at risk of subsequent growth impairment (1, 2, 3) . Some of these children can be shown in conventional pharmacological stimulation tests to become growth hormone (GH) deficient (1, 4 [2, 6] .
GH deficiency may follow cranial irradiation, the probability depending on the total radiation dose received by the hypothalamus. Some children can be shown to have unequivocal classical GH deficiency. Our studies seem to suggest that a few children retain the ability to secrete GH in response to pharmacological stimulation but secrete GH suboptimally during sleep [5] . When only human GH was available for treatment, the HSHGHC imposed strict criteria which had to be met before therapeutic GH could be supplied. Children with peak serum GH concentrations greater than 15mu/L during pharmacological stimulation tests were usually denied treatment. Now that biosynthetic GH is readily available, albeit at a price, such criteria no longer apply. We have long suspected that the figure of 15mU/L is too low to distinguish which children are likely to benefit from exogenous GH therapy. We would suggest that biosynthetic GH 
